Experience with extracorporeal elimination therapy in myasthenia gravis
Language English Country Great Britain, England Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
22018894
DOI
10.1016/j.transci.2011.10.003
PII: S1473-0502(11)00165-0
Knihovny.cz E-resources
- MeSH
- Time Factors MeSH
- Hemofiltration methods MeSH
- Middle Aged MeSH
- Humans MeSH
- Myasthenia Gravis therapy MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Plasma Exchange methods MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
We describe our experience with plasma exchange (PE) and immunoadsorption in patients with myasthenia gravis. The group of 27 patients consists of 21 patients treated with PE and 6 patients who received immunoadsorption. PE therapy led to stabilization in 20 patients. In patients treated with immunoadsorption, therapy could be discontinued in 2 patients after 13 months of therapy, and the other 4 patients were stabilized without myasthenic crises after 6-9 years of therapy. Extracorporeal elimination therapy through PE or immunoadsorption is effective and sometimes life saving and is safe in the hands of an experienced team (6% complication rate).
References provided by Crossref.org
